A human cytomegalovirus (HCMV) vaccine is urgently needed to protect against primary infection and enhance existing immunity in HCMV-infected individuals (HCMV+). Using sera from HCMV+ glycoprotein B/MF59 vaccine recipients prior to transplant, we investigated the composition of the immune response. Vaccination boosted preexisting humoral responses in our HCMV+ cohort but did not promote de novo responses against novel linear epitopes. This suggests that prior natural infection has a profound effect on shaping the antibody repertoire and subsequent response to vaccination ("original antigenic sin"). Thus, vaccination of HCMV+ may require strategies of epitope presentation distinct from those intended to prevent primary infection.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6581893 | PMC |
http://dx.doi.org/10.1093/infdis/jiz089 | DOI Listing |
J Infect Chemother
January 2025
Division of Infectious Diseases, Department of Pediatrics, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan; Division of Immunology, Department of Pediatrics, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
Cytomegalovirus (CMV) infection remains one of the most common and challenging post-transplant infections. Children with inborn errors of immunity (IEI) and T-cell dysfunction are at high risk for CMV infection, which can be complicated by refractory and/or resistant cases. This case describes a Nepalese girl with MHC class II deficiency, who presented at 3 months of age with CMV and Pneumocystis jirovecii pneumonia.
View Article and Find Full Text PDFViruses
January 2025
Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
In this narrative review, we explore the burden and risk factors of various herpesvirus infections in patients receiving chimeric antigen receptor T-cell (CAR-T) therapy or bispecific antibodies (BsAb) for the treatment of hematologic malignancies. Antiviral prophylaxis for herpes simplex/varicella zoster viruses became part of the standard of care in this patient population. Breakthrough infections may rarely occur, and the optimal duration of prophylaxis as well as the timing of recombinant zoster immunization remain to be explored.
View Article and Find Full Text PDFViruses
January 2025
Emeritus, Department of Microbiology & Immunology, Stanford Medical School, Stanford University, Stanford, CA 94305, USA.
This volume presents research and reviews bringing forward new insights into cytomegalovirus (CMV) pathogenesis and biology; CMV is a herpesvirus that has long been recognized as being medically significant [...
View Article and Find Full Text PDFViruses
January 2025
Virology Department, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Cytomegalovirus infections and reactivations are more frequent in people living with HIV (PLWH) and have been associated with increased risk of HIV progression and immunosenescence. We explored the impact of combination antiretroviral therapy (cART) on latent CMV infection in 225 young adults parenterally infected with HIV during childhood. Anti-CMV IgG antibodies were present in 93.
View Article and Find Full Text PDFPathogens
January 2025
Department of Infection, Immunity and Inflammation, Great Ormond Street Institute of Child Health, University College London, London WC1N 1EH, UK.
Cytomegalovirus (CMV) is a ubiquitous virus that infects most of the human population and causes significant morbidity and mortality, particularly among immunocompromised individuals. Understanding CMV's genetic diversity and evolutionary dynamics is crucial for elucidating its pathogenesis and developing effective therapeutic interventions. This review provides a comprehensive examination of CMV's genetic diversity and evolution, focussing on the role of different genotypes in viral pathogenesis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!